Novel agents in osteoporosis

Indian Journal of Pharmacology

Volumn 36, Issue 1, 2004, Pages 48-49

  Shah, H D ^a  

^a L M COLLEGE OF PHARMACY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM;

BONE DENSITY; BONE MASS; BONE MINERAL; BONE STRUCTURE; BONE TURNOVER; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FEMALE; HUMAN; NOTE; POSTMENOPAUSE OSTEOPOROSIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; TREATMENT PLANNING; VERTEBRA FRACTURE;

EID: 1042309473     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (14)

1. Meunier PJ, Slosman D, Delmas PD, et al. The strontium salt S-12911: a new candidate for the treatment of osteoporosis. Osteoporos Int 1996;6:S241.
2. Kaufman JM, Devogelaer JP, Raeman F, et al. Prevention and treatment of postmenopausal osteoporosis, National consensus of the "Belgian Bone Club." Clin Rheum 1997;16:343-5.
3. Reginster JY, Jupsin I, Deroisy R, et al. Prevention of postmenopausal bone loss by rectal calcitonin. Calcif Tissue Int 1995;56:539-42.
4. Kaufmann RF, Bryant HU. Effective therapeutic management of the postmenopausal state will be a cornerstone in strategies for preserving or improving women's health in the 21st century. Selective estrogen receptor modulators. Drugs New Prospect 1995;8:531-9.
5. Balfour JA, Goa KL. Raloxifene. Drugs Aging 1998;12:335-42.
6. Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine or estrogen effects on reproductive and non-reproductive tissues in ovariectomized rats. FASEB J 1996;10:905-12.
7. Ettinger B, Black MD, Mitlak BH, et al. Reduction of vertebral risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 1999;282:637-45.
8. Maricic M, Adachi JD, Sarkar S, et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002;162:1140-3.
9. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-years results from the MORE trial. Breast Cancer Res Treat 2001;65:125-34.
10. Su Y, Bonet J, Deloffre P, Tsouderos Y, Baron R. The strontium salt S12911 inhibits the expression of carbonic anhydrase and the vitronectin receptor in chicken bone marrow cultures and bone resorption in mouse calvaria and isolated rat osteoclasts. J Bone Miner Res 1992;7:306.
11. Ammann P, Rizzoli R, Deloffre P, Tsouderos Y, Meyer JM, Bonjour JP. The increase in vertebral bone mass induced in intact rats by long-term administration of the strontium salt S12911 is directly correlated with vertebral bone strength. Osteoporos Int 1996;6:259.
12. Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C. Prevention of early postmenopausal bone loss by strontium ranelate: a randomized, two-year, double-blind, dose-ranging, placebo-controlled trial. Osteoporos Int 2002;13:925-31.
13. Reginster JY, Spector T, Badurski J, et al. A short-term run-in study can significantly contribute to increasing the quality of long-term osteoporosis trials. The strontium ranelate phase III program. Osteoporos Int 2002;13:S30.
14. Reginster JY, Sawicki A, Devogelaer JP, et al. Strontium ranelate reduces the risk of hip fracture in women with postmenopausal osteoporosis. Osteoporos Int 2002;13:14.